KDKunal Dhiman

Kunal Dhiman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kunal Dhiman has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the therapeutic efficacy of phytochemicals in ameliorating cytotoxic effects of amyloid beta

    by Manas Chakraborty, Kunal Dhiman, Veer Gupta

    Background: There is lack of reliable treatment approaches to combat early cognitive impairment, as well as Alzheimer’s disease (AD). Since AD is a multifactorial disease, therapeutic approaches must be targeted on disease specific multiple‐biochemical pathways. There is a need to explore and test alternative disease modifiers which can target multiple metabolic pathways i.e., phytochemicals to combat such perturbations. This project will identify bioenergetic and viability changes that occur in response to amyloid pathology in cell models. Further, the therapeutic potential of a set of phytochemicals (safranal, berberine, taxifolin, bilobalide and vinpocetine) will be evaluated in mitigating such changes.Method: Neuroblastoma cell lines SH‐SY5Y cells and BE (2)‐M17 have been used to model AD in vitro. They were differentiated into mature human neurons using 10 µM retinoic acid. Amyloid beta 1‐42 (Ab42) is being used to induce neurotoxicity in the cells, which will be followed by treatment with phytochemicals. MTT (3‐(4, 5‐dimethylthiazolyl‐2)‐2, 5‐diphenyltetrazolium bromide) assay and flow cytometry will be used to evaluate cell viability, followed by sea horse assay to evaluate the oxygen consumption rate. Confocal microscopy will be used to confirm the images of amyloidosis and will be compared with the phytochemically treated group and the control group. Western blotting will be used to study the targeted pathways and proteins.Result: Differentiation of the cells have been successfully accomplished and confirmed through morphological changes in the cells. Treatment with Ab42 is currently under progress, which will be followed by treatment with phytochemicals. The protective effect of the phytochemicals will be evaluated through MTT, and sea horse assays and pathways will be studied using western blotting.Conclusion: This project will help to evaluate the therapeutic potential of selected phytochemicals, and thereby help to inform future pre‐clinical and clinical studies.

  • Open Access

    Development of a blood‐based biomarker signature for detection of cognitive impairment through a targeted metabolomics approach deciphering the association with depression

    by Manas Chakraborty, Kunal Dhiman, Veer Gupta

    Background: A series of pathological episodes set off the development of cognitive impairment, which precede years before the onset of clinical symptoms. Disrupted glucose and fatty acid metabolism notably contributes to the development of cognitive impairment and further advancement to clinical dementia. Disrupted metabolism leads to the secretion of various inflammatory eicosanoids leading to neuroinflammation. Alteration of some specific metabolites in plasma are noted during these metabolic changes. Depression is a key risk factor of cognitive impairment, and similar changes in plasma metabolites have observed in the pathophysiology of depression. This aim of this project is to establish a blood‐based biomarker signature for early detection of cognitive impairment in individuals with depression through quantifying plasma levels of metabolites associated with glucose and fatty acid metabolism in plasma samples from the participants of the Sydney Memory and Ageing Study (MAS).Method: Samples of 275 participants were randomly collected from baseline and 251 from an 8 year follow up study. At baseline there were 130 healthy participants, 93 participants with MCI, 36 participants with depression and 16 participants had both MCI and depression. Plasma samples were analysed to quantify the levels of fatty acids and carnitines using chemical derivatization – UPLC‐MRM/MS.Result: Significant correlations were observed between the biomarkers like FA040 butyric acid (P: 0.034), FA224 (P: 0.032), acotinic acid (P:0.027) with MMSE. Biomarkers like C70carnitine (P:0.010), C90carnitine (P: 0.033), C150carnitine (P: 0.016), C160 carnitines (P: 0.004) significantly correlated with GDS scales. Linear regression showed significance between C90 carnitine (P: 0.021; β: 0.139) ad GDS scale. Whereas linear regression showed significant relationship between FA224 (P: 040, β: ‐.122), acotinic acid (P: 0.042, β: ‐.122), FA040 butyric acid (P: 0.036, β: ‐.193) with MMSE indicative of cognitive impairment.Conclusion: The study will help to identify candidate metabolites of perturbed fatty acid metabolism and establish a plasma biomarker signature of early cognitive impairment, by deciphering the association with depression as a risk factor. An association will be established between central AD pathology and peripheral metabolic changes, and potential treatment options targeting the right biochemical pathways will be identified.

  • Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease

    by Bryant Lim, Christopher Fowler, Qiao-Xin Li, Christopher Rowe, Kunal Dhiman, Veer Bala Gupta, Colin L. Masters, James D. Doecke, Ralph N. Martins, Steven Collins, et al.


  • Open Access

    Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

    by Kunal Dhiman, Veer Bala Gupta, Victor L. Villemagne, Dhamidhu Eratne, Petra L. Graham, Christopher Fowler, Pierrick Bourgeat, Qiao‐Xin Li, Steven Collins, Ashley I. Bush, et al.

    Introduction This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation. Methods CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P < .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition. Discussion CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.


  • A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists?

    by Dhamidhu Eratne, Samantha M Loi, Nirbaanjot Walia, Sarah Farrand, Qiao-Xin Li, Shiji Varghese, Mark Walterfang, Andrew Evans, Ramon Mocellin, Kunal Dhiman, et al.

    Objective: Neurofilament light has shown promise as a biomarker for diagnosis, staging and prognosis in a wide range of neurological and neurodegenerative disorders. This study explored the utility of cerebrospinal fluid neurofilament light in distinguishing primary psychiatric disorders from neurodegenerative and neurological disorders, a common diagnostic dilemma for psychiatrists and neurologists. Methods: This cross-sectional retrospective pilot study assessed cerebrospinal fluid neurofilament light on patients referred to a tertiary neuropsychiatry service from 2009 to 2017 for diagnostic assessment of neuropsychiatric and neurocognitive symptoms, where a neurodegenerative disorder was a differential diagnosis, who received lumbar punctures as part of a comprehensive workup. The most recent gold-standard clinical consensus diagnosis was categorised into psychiatric disorder or neurodegenerative or neurological disorder. Data from healthy controls were available for comparison. Data extraction and diagnostic categorisation was blinded to neurofilament light results. Results: A total of 129 participants were included: 77 neurodegenerative or neurological disorder (mean age 57 years, including Alzheimer’s dementia, frontotemporal dementia), 31 psychiatric disorder (mean age 51 years, including schizophrenia, major depressive disorder) and 21 healthy controls (mean age 66 years). Neurofilament light was significantly higher in neurodegenerative or neurological disorder (M = 3560 pg/mL, 95% confidence intervals = [2918, 4601]) compared to psychiatric disorder (M = 949 pg/mL, 95% confidence intervals = [830, 1108]) and controls (M = 1036 pg/mL, 95% confidence intervals = [908, 1165]). Neurofilament light distinguished neurodegenerative or neurological disorder from psychiatric disorder with an area under the curve of 0.94 (95% confidence intervals = [0.89, 0.98]); a cut-off of 1332 pg/mL was associated with 87% sensitivity and 90% specificity. Conclusion: Cerebrospinal fluid neurofilament light shows promise as a diagnostic test to assist with the often challenging diagnostic dilemma of distinguishing psychiatric disorders from neurodegenerative and neurological disorders. Further studies are warranted to replicate and expand on these findings, including on plasma neurofilament light.


  • Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis

    by Kunal Dhiman, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins, Veer Bala Gupta

    Alzheimer’s disease (AD) is a multifactorial age-related brain disease. Numerous pathological events run forth in the brain leading to AD. There is an initial long, dormant phase before the clinical symptoms become evident. There is a need to diagnose the disease at the preclinical stage since therapeutic interventions are most likely to be effective if initiated early. Undoubtedly, the core cerebrospinal fluid (CSF) biomarkers have a good diagnostic accuracy and have been used in clinical trials as end point measures. However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology. The review is focused upon a panel of biomarkers that relate to different aspects of AD pathology, as well as various studies that have evaluated their diagnostic potential. The panel includes markers of neurodegeneration: neurofilament light chain and visinin-like protein (VILIP-1); markers of amyloidogenesis and brain amyloidosis: apolipoproteins; markers of inflammation: YKL-40 and monocyte chemoattractant protein 1; marker of synaptic dysfunction: neurogranin. These markers can highlight on the state and stage-associated changes that occur in AD brain with disease progression. A combination of these biomarkers would not only aid in preclinical diagnosis, but would also help in identifying early brain changes during the onset of disease. Successful treatment strategies can be devised by understanding the contribution of these markers in different aspects of disease pathogenesis.


  • Free radical scavenging potential and total phenolic and flavonoid content of Ziziphus mauritiana and Ziziphus nummularia fruit extracts

    by AnamikaGupta Dureja, Kunal Dhiman, Dureja Ag

    Background: Nowadays antioxidants have gained a lot of importance because of their potential as prophylactic and therapeutic agents in the diseases caused by free radicals. Presently, the active constituents from the natural sources are tested for their free radical scavenging potential. Plants are of enormous importance in the free radical and antioxidant field. Aim: The present study was carried out to evaluate the free radical potential, total phenolic and flavonoid content of edible and non-commercial fruits of Ziziphus mauritiana and Ziziphus nummularia belonging to the family Rhamnaceae. Materials and Methods: Free radical scavenging potential of methanolic extracts of the Ziziphus mauritiana and Ziziphus nummularia fruits (MEZM and MEZN) was evaluated by 1, 1-diphenyl-2-picryl-hydrazyl (DPPH) and hydrogen peroxide (H 2 O 2 ) method. The total phenolic content of the methanolic extracts of fruits was determined using gallic acid as a standard. The total flavonoid content was determined using the Aluminium chloride reagent and quercetin as standard. Statistical analysis: The results were statistically analysed with the Student's t-test. Results and Conclusions: The extracts showed significant free radical scavenging activity in a dose dependent manner when compared with ascorbic acid. The highest DPPH radical scavenging activity of MEZM and MEZN was found to be 79.5% and 77.5% respectively at concentration of 250 μg mL -1 . The H 2 O 2 scavenging effect of MEZM and MEZN was 73.4% and 71% respectively at a concentration of 250 μg mL -1 . IC 50 . The fruits can be used as a natural source of antioxidants in combating diseases caused by free radicals.


  • A Review on the Medicinally Important Plants of the Family Cucurbitaceae

    by K. Dhiman, A. Gupta, D.K. Sharma, N.S. Gill, A. Goyal

    A Review on the Medicinally Important Plants of the Family Cucurbitaceae


  • Evaluation of Free Radical Scavenging and Antiulcer Potential of Methanolic Extract of Benincasa hispida Seeds

    by N.S. Gill, K. Dhiman, P. Sharma, J. Bajwa, S. Sood, P.D. Sharma, B. Singh, M. Bali

    Evaluation of Free Radical Scavenging and Antiulcer Potential of Methanolic Extract of Benincasa hispida Seeds


  • Evaluation of Antioxidant and Antiulcer Activity of Traditionally Consumed Cucumis melo Seeds

    by N.S. Gill, J. Bajwa, K. Dhiman, S. Sood, P.D. Sharma, B. Singh, M. Bali

    Evaluation of Antioxidant and Antiulcer Activity of Traditionally Consumed Cucumis melo Seeds